DFCI Logo
DFCI Logo

Department of Radiation Oncology

researchers-in-lab-2-1223x481.jpg

Contact Us

If you are interested in learning more about our research, please email Joseph Mancias, MD, PhD.

EMAIL

Support Our Cancer Research

To learn more about the many ways you can support Dana-Farber's research initiatives with a philanthropic gift, please contact Rebecca Shortle at 617-632-4215 or rebecca_shortle@dfci.harvard.edu.

Donate Today

The Department of Radiation Oncology is committed to combining advances in clinical research and laboratory research with developments in radiation physics — to promote a better understanding of the biology of cancer and the improvement of treatment methods.

Our Research Themes

The unifying research aim of the department is the understanding of genomic instability in human cancer in order to tailor therapies for cancer patients. Departmental research is focused on the treatment of tumors and on increasing the understanding of treatments at the molecular and cellular levels. Our research involves collaboration with other fields as we aim to better identify and treat cancer.

Our members' research laboratories are advancing the department's aim and focus in the following ways:

radiation-oncology-1735x589.jpg
Our investigators are bringing new techniques to patients of radiation oncology through scientific research.
radiation-oncology-3735x589.jpg
Our research involves innovative collaboration with other fields as we aim to better identify and treat cancer.

Biology

haas-kogan-lab556x381.jpg

Haas-Kogan Lab: Exploring Signaling Pathways

Daphne Haas-Kogan, MD, is studying signaling pathways commonly activated in gliomas and pediatric malignancies and inhibitors that target elements within these pathways. Her laboratory attempts to promote progress not only in defining the genomic landscape of human gliomas and pediatric cancers, but also in sensible implementation of targeted therapeutics to maximally impact signaling response.

makrigiorgos-lab556x381.jpg

Makrigiorgos Lab: Identifying Tumor Signatures

Gerassimos (Mike) Makrigiorgos, PhD, is studying the identification and tracing of tumor signatures in cancer samples. His laboratory has a special interest in developing new technologies for cancer molecular diagnostics and molecular profiling for personalized medicine. He has developed a range of methodologies for evaluation of tumor-specific genetic changes, such as mutation and methylation.

mancias-lab556x381.jpg

Mancias Lab: Understanding the Biology of Pancreatic Cancer

Joseph Mancias, MD, PhD, is focused on the study of pancreatic cancer, particularly the critical aspects of the biology of pancreatic cancer in order to develop novel therapeutic approaches. The Mancias Lab combines biochemical, quantitative mass spectrometry-based proteomic, gene editing, cell biological, and mouse modeling techniques to advance our understanding of pancreatic cancer.

mouw-lab556x381.jpg

Mouw Lab: DNA Repair Pathway Alterations in Tumors

Kent Mouw, MD, PhD, is using a combination of genomic and functional approaches to study the role of DNA repair pathway alterations in tumor behavior and treatment response. Along with collaborators, Mouw is working to identify DNA repair biomarkers to guide the use of chemotherapy, radiation, and targeted agents.

price-lab556x381.jpg

Price Lab: Uncovering DNA Repair Mechanisms

Brendan Price, PhD, has made major advances in understanding the role of the ataxia-telangiectasia gene product (ATM) as a sensor of DNA damage and a regulator of radiation resistance in the irradiated cell. The findings of the Price Lab offer great potential in the rational design of combination cancer therapy specifically targeting components of the ATM-Tip60 complex and the proteins that contribute to maintaining histone methylation marks on the chromatin.

Physics

aerts-lab556x381.jpg

Aerts Lab: Using Imaging Data in Radiation Research

Hugo Aerts, PhD, studies the role of imaging data for precision medicine. Aerts's laboratory focuses on the application of advanced computational approaches, such as radiomics, to quantify the tumor phenotype using advanced data characterization algorithms, which in turn can be used to develop biomarkers that complement those derived from biopsies.

berbeco-lab556x381.jpg

Berbeco Lab: Combining Nanomedicine and Radiation Therapy

Ross Berbeco, PhD, is studying methods for improving the accuracy and precision of clinical radiation therapy delivery. Additionally, Berbeco is studying the combination of novel nanoparticle formulations with clinical radiation therapy delivery.

Support Our Cancer Research

To learn more about the many ways you can support Dana-Farber's research initiatives with a philanthropic gift, please contact Rebecca Shortle at 617-632-4215 or rebecca_shortle@dfci.harvard.edu.

Donate Today